#SpecialGain

Plan to sell one policy holding stock between February and March 2026, recording a gain on sale of investment securities of 4,043 million yen. Expected to be recorded as a special gain in the fourth quarter.

The planned purchase price for the tender offer was revised from 18,800 yen to 20,600 yen per common share, increasing the total planned sale amount from 37.6 billion yen to 41.2 billion yen. The tender offer period has been extended from February 12, 2026, to March 23, 2026.

The Company sold 444,038 shares of Hisamitsu Pharmaceutical Co., Inc. held, at 6,082 yen per share, totaling 2,700 million yen, and will record special gains of 2,543 million yen in the fiscal year ending March 2026.

In the third quarter of the fiscal year ending March 2026, a special gain of JPY 5,169 million was recorded related to additional acquisition of equity interest in G2/Spryte Holdco, LLC.